Director Gavin Corcoran receives 16,000 Verrica (VRCA) stock options at $6.04

Rhea-AI Filing Summary

Verrica Pharmaceuticals director Gavin Corcoran received a grant of stock options covering 16,000 shares of common stock at an exercise price of $6.04 per share. These options vest in 12 equal monthly installments beginning on July 5, 2026, and will be fully vested by the next annual stockholder meeting, subject to his continued service. Following this compensation award, Corcoran holds 16,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Corcoran Gavin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 16,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 16,000 options Exercise price: $6.04 per share Expiration date: June 4, 2036 +4 more

7 metrics

Option grant size 16,000 options Stock Option (right to buy) covering common stock

Exercise price $6.04 per share Conversion or exercise price of stock options

Expiration date June 4, 2036 Option expiration for 16,000-share grant

Shares underlying options 16,000 shares Underlying Verrica common stock for the option grant

Post-grant option holdings 16,000 options Total derivative holdings following the transaction

Vesting start date July 5, 2026 Monthly vesting begins for the option grant

Vesting schedule 12 monthly installments Equal monthly vesting, fully vested by next annual meeting

Key Terms

Stock Option (right to buy), Common Stock, exercise price, vest and become exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 6.0400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments"

annual meeting of stockholders financial

"fully vested on the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corcoran Gavin

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 WEST GAY STREET, SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.04	06/05/2026		A		16,000		(1)	06/04/2036	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.

	/s/ Gavin Corcoran	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Verrica Pharmaceuticals (VRCA) director Gavin Corcoran report in this Form 4?

Gavin Corcoran reported receiving a stock option grant for 16,000 shares of Verrica Pharmaceuticals common stock. The options were granted as compensation, carry a $6.04 exercise price, and are held directly, increasing his derivative-based exposure to the company.

What are the key terms of Gavin Corcoran’s new Verrica (VRCA) stock options?

The new stock options cover 16,000 shares of Verrica common stock at a $6.04 exercise price and expire on June 4, 2036. They represent a long-dated incentive aligning the director’s potential upside with future company performance over a multi-year period.

How do Gavin Corcoran’s Verrica (VRCA) options vest over time?

The 16,000 Verrica options vest in 12 equal monthly installments starting July 5, 2026. They will in any event be fully vested by the date of the next annual meeting of stockholders, assuming Corcoran continues to serve as a director through each vesting date.

Did Gavin Corcoran buy or sell any Verrica (VRCA) shares in the market?

The filing shows a compensation-related acquisition of stock options, not an open-market trade. Corcoran received 16,000 options for zero cost per option, with a $6.04 exercise price, and there were no reported purchases or sales of common shares in this transaction.

What is Gavin Corcoran’s Verrica (VRCA) option position after this Form 4?

After the reported grant, Corcoran holds 16,000 stock options directly, each exercisable for one share of Verrica common stock. The filing does not show additional derivative positions, so this award defines his visible option-based stake as of the transaction date.

When do Gavin Corcoran’s Verrica (VRCA) stock options expire?

The 16,000 Verrica stock options granted to Gavin Corcoran expire on June 4, 2036. This long expiration period provides an extended timeframe during which he may choose to exercise the options, depending on future company performance and Verrica’s share price.